Atle Fund Management AB
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed July 14, 2025), Atle Fund Management AB reported 37 stock positions worth $233.7 million. Its top holding was Eli Lilly (LLY) at 12.9% of the portfolio, followed by Abbvie (ABBV, 6.9%) and Boston Scientific (BSX, 5.8%). Compared with Q1 2025, it opened 1 new position, sold out of 1, added to 23 and reduced 13. The biggest buy was Neurocrine Biosciences (NBIX, shares +16%) and the biggest sale Unitedhealth (UNH, shares −47%).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $233.7M (Q2 2025)
- SEC Filing
- 0001381843-25-000006 ↗ filed Jul 14, 2025
Holdings Value
Holdings 37 stocks · $233.7M
| LLY Eli Lilly & Co. | 12.92% | 38,721 | $30.2M | Add +11.9% |
| ABBV Abbvie Inc. | 6.91% | 86,933 | $16.1M | Reduce -2.6% |
| BSX Boston Scientific Corp. | 5.80% | 126,185 | $13.6M | Reduce -4.6% |
| NBIX Neurocrine Biosciences Inc. | 4.75% | 88,392 | $11.1M | Add +16.5% |
| MRK Merck & Co. Inc. | 4.71% | 139,172 | $11.0M | Add +9.0% |
| SYK Stryker Corp. | 4.65% | 27,466 | $10.9M | Add +19.4% |
| VRTX Vertex Pharmaceuticals Inc. | 4.64% | 24,328 | $10.8M | Add +6.7% |
| ISRG Intuitive Surgical Inc. | 4.32% | 18,559 | $10.1M | Add +20.9% |
| TMO Thermo Fisher Scientific Inc. | 4.21% | 24,266 | $9.8M | Add +6.2% |
| COR Cencora Inc. | 4.04% | 31,466 | $9.4M | Reduce -0.3% |
| GILD Gilead Sciences Inc. | 3.47% | 73,165 | $8.1M | Reduce -5.0% |
| BBIO Bridgebio Pharma Inc. | 3.06% | 165,480 | $7.1M | Add +9.3% |
| AMGN Amgen Inc. | 2.86% | 23,894 | $6.7M | Reduce -10.1% |
| ALKS Alkermes PLC | 2.78% | 227,224 | $6.5M | Add +5.8% |
| ONC Beone Medicines Ltd.-ADR | 2.53% | 24,386 | $5.9M | Reduce -3.0% |
| MIRM Mirum Pharmaceuticals Inc. | 2.33% | 106,912 | $5.4M | Add +38.4% |
| UFPT Ufp Technologies Inc. | 2.29% | 21,886 | $5.3M | Add +3.0% |
| CAH Cardinal Health Inc. | 1.93% | 26,797 | $4.5M | Reduce -3.2% |
| EW Edwards Lifesciences Corp. | 1.92% | 57,360 | $4.5M | Reduce -3.9% |
| VRNA Verona Pharma Ltd. | 1.91% | 47,100 | $4.5M | Add +35.8% |
| DXCM Dexcom Inc. | 1.90% | 50,872 | $4.4M | Add +11.0% |
| IRTC Irhythm Holdings Inc. | 1.67% | 25,302 | $3.9M | Add +23.1% |
| SLNO Soleno Therapeutics Inc. | 1.45% | 40,532 | $3.4M | Add +9.3% |
| MRUS Merus NV | 1.35% | 59,889 | $3.2M | Add +69.7% |
| RVMD Revolution Medicines Inc. | 1.30% | 82,275 | $3.0M | Add +49.7% |
| NAMS Newamsterdam Pharma Co. NV | 1.22% | 157,223 | $2.8M | Add +45.9% |
| KRYS Krystal Biotech Inc. | 1.19% | 20,158 | $2.8M | Reduce -14.2% |
| HRMY Harmony Biosciences Holdings | 1.17% | 86,274 | $2.7M | Reduce -5.5% |
| AUTL Autolus Therapeutics PLC | 1.08% | 1,105,461 | $2.5M | Add +130.5% |
| UNH Unitedhealth Group Inc. | 1.06% | 13,727 | $2.5M | Reduce -46.8% |
| MREO Mereo Biopharma Group PL-ADR | 0.89% | 764,901 | $2.1M | Add +96.1% |
| SMMT Summit Therapeutics Inc. | 0.84% | 92,737 | $2.0M | Reduce -11.7% |
| ACLX Arcellx Inc. | 0.73% | 25,732 | $1.7M | Reduce -41.7% |
| BCAX Bicara Therapeutics Inc. | 0.59% | 147,380 | $1.4M | Add +23.0% |
| IRON Disc Medicine Inc. | 0.56% | 24,652 | $1.3M | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.52% | 175,582 | $1.2M | Add +78.6% |
| JANX Janux Therapeutics Inc. | 0.49% | 49,820 | $1.2M | Add +6.4% |
Portfolio Sells Q1 2025 → Q2 2025
| UNH Unitedhealth Group Inc. | Reduce -46.8% | 1.06% | −4.90 |
| ABBV Abbvie Inc. | Reduce -2.6% | 6.91% | −1.35 |
| AMGN Amgen Inc. | Reduce -10.1% | 2.86% | −0.80 |
| KRYS Krystal Biotech Inc. | Reduce -14.2% | 1.19% | −0.68 |
| ACLX Arcellx Inc. | Reduce -41.7% | 0.73% | −0.55 |
| ONC Beone Medicines Ltd.-ADR | Reduce -3.0% | 2.53% | −0.49 |
| GILD Gilead Sciences Inc. | Reduce -5.0% | 3.47% | −0.34 |
| HRMY Harmony Biosciences Holdings | Reduce -5.5% | 1.17% | −0.17 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.11 |
| BSX Boston Scientific Corp. | Reduce -4.6% | 5.80% | −0.09 |
| SMMT Summit Therapeutics Inc. | Reduce -11.7% | 0.84% | −0.05 |
| EW Edwards Lifesciences Corp. | Reduce -3.9% | 1.92% | +0.01 |
| COR Cencora Inc. | Reduce -0.3% | 4.04% | +0.16 |
| CAH Cardinal Health Inc. | Reduce -3.2% | 1.93% | +0.24 |
Portfolio Buys Q1 2025 → Q2 2025
| NBIX Neurocrine Biosciences Inc. | Add +16.5% | 4.75% | +1.05 |
| ISRG Intuitive Surgical Inc. | Add +20.9% | 4.32% | +0.96 |
| VRNA Verona Pharma Ltd. | Add +35.8% | 1.91% | +0.93 |
| SYK Stryker Corp. | Add +19.4% | 4.65% | +0.87 |
| MIRM Mirum Pharmaceuticals Inc. | Add +38.4% | 2.33% | +0.79 |
| AUTL Autolus Therapeutics PLC | Add +130.5% | 1.08% | +0.75 |
| BBIO Bridgebio Pharma Inc. | Add +9.3% | 3.06% | +0.75 |
| IRTC Irhythm Holdings Inc. | Add +23.1% | 1.67% | +0.72 |
| MRUS Merus NV | Add +69.7% | 1.35% | +0.69 |
| IRON Disc Medicine Inc. | New | 0.56% | +0.56 |
| DXCM Dexcom Inc. | Add +11.0% | 1.90% | +0.52 |
| MREO Mereo Biopharma Group PL-ADR | Add +96.1% | 0.89% | +0.50 |
| RVMD Revolution Medicines Inc. | Add +49.7% | 1.30% | +0.44 |
| UFPT Ufp Technologies Inc. | Add +3.0% | 2.29% | +0.39 |
| LLY Eli Lilly & Co. | Add +11.9% | 12.92% | +0.30 |
| CRBP Corbus Pharmaceuticals Holdi | Add +78.6% | 0.52% | +0.29 |
| SLNO Soleno Therapeutics Inc. | Add +9.3% | 1.45% | +0.28 |
| NAMS Newamsterdam Pharma Co. NV | Add +45.9% | 1.22% | +0.24 |
| JANX Janux Therapeutics Inc. | Add +6.4% | 0.49% | −0.07 |
| BCAX Bicara Therapeutics Inc. | Add +23.0% | 0.59% | −0.10 |
| VRTX Vertex Pharmaceuticals Inc. | Add +6.7% | 4.64% | −0.25 |
| MRK Merck & Co. Inc. | Add +9.0% | 4.71% | −0.34 |
| ALKS Alkermes PLC | Add +5.8% | 2.78% | −0.35 |
| TMO Thermo Fisher Scientific Inc. | Add +6.2% | 4.21% | −0.81 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |